Shaping the immune response. Selecta Biosciences is focused on dramatically improving human health through its novel and proprietary Synthetic Vaccine Particle (SVP™) platform. Traditional vaccine technology has focused on prophylactic humoral immunity, while traditional immunotherapies induce general immune suppression. Selecta’s technology enables potent antigen-specific immune therapies by rational design of SVP™ that can co-deliver specific antigen(s) and immunomodulator(s) to relevant immune cells. The composition of SVP™ immunotherapies can be engineered to induce either humoral or cellular immunity for therapeutic as well as prophylactic applications. In addition, SVP™ can be tailored to induce antigen-specific immune tolerance. Selecta's SVP™ platform is modular and flexible, enabling the optimization of immunotherapies against a wide variety of antigens using a broad range of immunomodulating agents. The biodegradable nanoparticles are based on materials that are FDA approved and have been in clinical use for more than 30 years. Selecta works on stimulatory immunotherapies in infectious diseases, cancer, and respiratory diseases. The technology has been adapted to induce both durable cellular and humoral responses. In tolerance, the company applies its technology to autoimmune diseases, allergies, transplantation, and orphan indications such as hemophilia and protein replacement therapy.
The image above illustrates the modularity of Selecta’s proprietary self-assembling nanoparticle technology. The SVP™ platform uniquely incorporates the essential elements required for an antigen-specific and robust immune modulation.
SVP™ nanoparticles are safe, scalable and produced under GMP conditions. The first SVP™ based immunotherapy entered Phase 1 clinical development in 2011.
CEO Werner Cautreels explaining Selecta’s platform